Revolution Medicines, Inc. Common Stock
RVMD
$188.07
-0.61%
Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, leveraging structure-based drug discovery to create small molecules that bind directly to RAS variants. As a pioneer in the RAS inhibitor space, it stands out for its proprietary RAS(ON) Inhibitor platform targeting a historically undruggable class of mutations. The stock has surged over 140% year-to-date following a Phase 3 pancreatic cancer trial that doubled survival versus chemotherapy, driving intense investor focus on its lead candidate daraxonrasib and a recent $2.2 billion capital raise to fund its ambitious pipeline. The key debate centers on whether the clinical promise justifies the pre-revenue valuation and dilution from the upsized offering.…
RVMD
Revolution Medicines, Inc. Common Stock
$188.07
Related headlines
Investment Opinion: Should I buy RVMD Today?
Rating: Buy. Revolution Medicines is a high-risk, high-reward biotech with a validated platform and strong balance sheet, but investors must accept pre-revenue volatility. The consensus is Strong Buy with an average target of $207, implying 9.4% upside.
Supporting Evidence: The Phase 3 pancreatic cancer data is a game-changer, doubling survival versus chemo. The $2.2B cash raise funds the pipeline through key milestones. Analyst targets range from $151 to $263, with a strong buy consensus. The stock's 408% one-year return and 392% relative strength versus the S&P 500 confirm market leadership. However, the P/B of 9.3x is elevated versus peers, and the company has zero revenue.
Risks & Conditions: The biggest risks are clinical failure, regulatory delay, and dilution. This Buy would downgrade to Hold if the stock exceeds the average target without new catalysts, or to Sell if a Phase 3 trial fails. The stock is overvalued on traditional metrics but fairly valued relative to its clinical potential and cash position. Investors should size positions accordingly and monitor upcoming data readouts.
Sign up to view all
RVMD 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The Phase 3 data provides strong validation, and the capital raise removes near-term financing risk. However, the stock's valuation is stretched, and binary clinical risk remains. The base case of gradual approval and commercialization is most likely, but the bull case has a meaningful probability given the unmet need in pancreatic cancer. Upgrades would come from FDA approval and early sales; downgrades from regulatory setbacks or competitor advances.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $207.00 and implied upside of +10.1% versus the current price.
Average Target
$207.00
0 analysts
Implied Upside
+10.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$151 - $263
Analyst target range
Revolution Medicines is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.27 on a 1-5 scale). The average price target is $207.00, implying approximately 9.4% upside from the current price of $189.23. The distribution leans heavily bullish, with no sell ratings and a majority of buy or outperform ratings. Recent institutional ratings show consistent upgrades and reiterations from firms like Guggenheim, HC Wainwright, Mizuho, and Wedbush, all maintaining positive stances following the Phase 3 data and capital raise. The target range spans from a low of $151.00 to a high of $263.00, representing a wide spread of $112.00, which reflects high uncertainty typical of pre-revenue biotechs. The high target of $263 implies 39% upside and likely assumes successful commercialization of daraxonrasib and pipeline expansion, while the low target of $151 suggests a 20% downside if clinical or regulatory setbacks occur. The wide spread indicates divergent views on the probability of success and peak sales potential. The strong buy consensus and recent positive ratings suggest analysts are confident in the near-term catalysts, but the wide range underscores the binary risk inherent in the stock.
Bulls vs Bears: RVMD Investment Factors
Revolution Medicines presents a high-conviction bull case driven by a Phase 3 breakthrough in pancreatic cancer, strong analyst support, and a well-capitalized balance sheet. However, the bear case highlights zero revenue, widening losses, extreme valuation multiples, and binary clinical risk. Currently, the bull case has stronger evidence given the positive data and $2.2B cash runway, but the stock's valuation leaves little room for error. The single most important tension is whether daraxonrasib's clinical success will translate into commercial revenue and profitability before cash burn forces further dilution or a financing event.
Bullish
- Phase 3 Success in Pancreatic Cancer: Daraxonrasib doubled survival versus chemotherapy in a Phase 3 pancreatic cancer trial, a historically difficult-to-treat disease. This breakthrough positions RVMD as a potential standard-of-care and drove the stock up 140% YTD.
- Strong Analyst Consensus and Upside: 21 analysts rate RVMD a Strong Buy (mean 1.27 on 1-5 scale) with an average target of $207, implying 9.4% upside. The high target of $263 suggests 39% potential gain if commercialization succeeds.
- Robust Balance Sheet Post Capital Raise: The $2.2 billion upsized offering in April 2026 provides ample cash runway, with a current ratio of 7.14 and debt-to-equity of only 0.097. This de-risks pipeline advancement through key milestones.
- Massive Market Opportunity in RAS Cancers: RAS mutations are present in ~30% of all cancers, including pancreatic, colorectal, and lung. RVMD's RAS(ON) platform targets a historically undruggable class, offering a multi-billion-dollar peak sales opportunity.
Bearish
- Pre-Revenue with Widening Losses: RVMD has zero product revenue and net losses widened from -$213M in Q1 2025 to -$454M in Q1 2026. Trailing twelve-month net loss is -$1.37B, with negative free cash flow of -$1.07B.
- Extreme Valuation on Traditional Metrics: With no revenue, P/S is undefined. Price-to-book of 9.3x is near the top of its historical range (2.2x-12.8x) and well above the biotech industry average of 3-5x, implying optimistic expectations.
- Significant Shareholder Dilution: The $2.2 billion capital raise increased shares outstanding from ~188M to ~198M (5.3% dilution). Further dilution is likely as cash burn continues, with negative FCF yield of -16.9x.
- Binary Clinical and Regulatory Risk: As a pre-revenue biotech, RVMD's valuation hinges on daraxonrasib's approval and commercial success. Any clinical setback or regulatory delay could trigger a 50%+ decline, as seen with many biotech stocks.
RVMD Technical Analysis
Revolution Medicines is in a powerful sustained uptrend, with the stock up 408.4% over the past year and currently trading at $189.23, just 2.4% below its 52-week high of $193.825. The price sits at 97.6% of its 52-week range, indicating strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the near term. The 1-year relative strength versus the S&P 500 is an extraordinary 391.9%, confirming the stock's leadership in the biotech sector. Short-term momentum remains robust, with a 1-month gain of 11.5% and a 3-month gain of 39.9%, both significantly outpacing the S&P 500's 0.8% and 3.5% returns over the same periods. The 1-month relative strength of 10.7% indicates continued outperformance, though the pace has moderated from the explosive 60.9% six-month gain, suggesting a consolidation phase after the April rally. The stock's beta of 1.376 implies 37.6% more volatility than the market, which is typical for a high-growth biotech. Key support lies at the 52-week low of $34.00, a level not tested since early 2025, while resistance is at the 52-week high of $193.825. A breakout above $193.825 could signal a continuation of the uptrend toward analyst targets, while a breakdown below the recent consolidation zone near $180 would indicate a potential pullback. The current RSI is not provided, but the price action near highs suggests the stock may be approaching overbought territory.
Beta
1.38
1.38x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$34-$195
Price range past year
Annual Return
+396.2%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | +1.4% |
| 3m | +29.9% | +3.9% |
| 6m | +93.2% | +6.3% |
| 1y | +396.2% | +16.0% |
| ytd | +138.0% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is a pre-revenue biotech with zero product revenue, reporting $0 in revenue for the latest quarter (Q1 2026) and all prior quarters. The company's only revenue source is collaboration revenue, which was $7.0 million in a prior period, but this is negligible relative to its market cap. The growth trajectory is entirely dependent on clinical milestones; the recent Phase 3 success for daraxonrasib in pancreatic cancer is a major catalyst, but the company has yet to commercialize any product. Net losses have been widening, from -$213.4 million in Q1 2025 to -$453.8 million in Q1 2026, reflecting escalating R&D spending (from $205.7 million to $344.0 million year-over-year). The company is deeply unprofitable, with a trailing twelve-month net income of -$1.37 billion and a negative net margin. Gross margin is effectively zero as there is no product revenue, and operating margins are deeply negative. The trajectory is toward larger losses as the pipeline advances, though the $2.2 billion capital raise provides a cash runway to fund operations. The balance sheet shows a debt-to-equity ratio of just 0.097, indicating minimal leverage, and a current ratio of 7.14, suggesting ample liquidity. However, free cash flow is deeply negative, at -$1.07 billion over the trailing twelve months, and the company relies on external financing—evidenced by the $2.2 billion equity offering in April 2026. ROE is -69.3%, reflecting the large net losses relative to shareholders' equity. The negative free cash flow yield (price-to-FCF ratio of -16.9) underscores the cash burn, but the strong balance sheet and recent capital raise mitigate near-term solvency risk.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Since Revolution Medicines has negative net income and negative EBITDA, the most appropriate valuation metric is the price-to-sales (P/S) ratio, but the company has zero revenue, making P/S undefined. Therefore, we use the enterprise value-to-EBITDA (EV/EBITDA) ratio, which is -13.68, indicating the company is valued at a multiple of negative earnings—common for pre-revenue biotechs. The trailing P/E is -13.39, and the forward P/E is -32.62, reflecting expectations of continued losses. The gap between trailing and forward P/E suggests the market anticipates even larger losses per share in the coming year, likely due to increased R&D spending. Peer comparison is challenging as most biotech peers also have negative earnings; however, the EV/EBITDA of -13.68 is less negative than some early-stage peers, implying a premium due to the promising pipeline. The price-to-book ratio of 9.28 is high relative to the industry average of around 3-5x for biotechs, indicating investors are paying a significant premium for the company's assets and future potential. Historically, the P/B ratio has ranged from 2.2x in late 2023 to 12.8x in Q1 2026, and the current 9.3x is near the top of its historical band, suggesting the market is pricing in optimistic expectations for clinical success. The PEG ratio is negative (-0.20) due to negative earnings, rendering it uninformative. Overall, the valuation is stretched on traditional metrics but is typical for a high-potential pre-revenue biotech with positive clinical data.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Revolution Medicines has zero product revenue and is deeply unprofitable, with net losses widening from -$213.4 million in Q1 2025 to -$453.8 million in Q1 2026. The company's trailing twelve-month free cash flow is -$1.07 billion, and it relies entirely on external financing. Although the $2.2 billion capital raise provides near-term liquidity, the negative free cash flow yield of -16.9x indicates continued cash burn. The ROE of -69.3% and negative net margins underscore the lack of profitability, and any delay in commercialization could force additional dilutive financing.
Market & Competitive Risks: RVMD trades at a price-to-book ratio of 9.3x, near the top of its historical range and well above the biotech industry average of 3-5x, implying elevated expectations. The stock's beta of 1.376 makes it highly sensitive to market downturns and sector rotation. Competitive threats include other RAS-targeting therapies from Amgen, Mirati, and others. The wide analyst target range ($151-$263) reflects high uncertainty, and a shift in risk appetite could compress multiples significantly.
Worst-Case Scenario: If daraxonrasib fails to gain regulatory approval or faces a safety/efficacy issue, the stock could collapse to its 52-week low of $34.00, representing a -82% decline from the current price of $189.23. Even a less severe setback, such as a delay or competitor advance, could drive the stock to the analyst low target of $151, a -20% loss. The binary nature of biotech investing means that a single negative data readout could erase years of gains.
FAQ
The key risks are: 1) Clinical/regulatory failure – daraxonrasib could fail to gain approval or face safety issues, causing a -82% decline to the 52-week low of $34. 2) Dilution – the $2.2B capital raise diluted shareholders by 5.3%, and further dilution is likely as cash burn continues (FCF -$1.07B TTM). 3) Valuation compression – the P/B of 9.3x is elevated and could contract if sentiment shifts. 4) Competition – other RAS inhibitors from Amgen and Mirati could erode market share.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $207-$263, driven by FDA approval and strong sales. Base case (45% probability) targets $180-$207, assuming gradual approval and commercialization. Bear case (25% probability) targets $34-$151, if clinical or regulatory setbacks occur. The base case is most likely, with the stock trading near analyst averages as investors await revenue inflection.
RVMD is overvalued on traditional metrics: it has zero revenue, negative earnings, and a price-to-book ratio of 9.3x, well above the biotech industry average of 3-5x and near its historical high of 12.8x. The EV/EBITDA of -13.7x reflects negative earnings. However, the valuation is typical for a pre-revenue biotech with positive Phase 3 data and a large market opportunity. The market is pricing in high probability of success for daraxonrasib, which may be justified given the unmet need.
RVMD is a compelling buy for aggressive growth investors willing to accept pre-revenue biotech risk. The stock has strong analyst support (Strong Buy consensus, average target $207, 9.4% upside) and a validated Phase 3 data set. However, the stock is overvalued on traditional metrics (P/B 9.3x vs industry 3-5x) and carries binary clinical risk. It is a good buy for those who believe daraxonrasib will achieve regulatory approval and commercial success, but not for risk-averse or short-term traders.
RVMD is best suited for long-term investment (3-5 years) given its pre-revenue status and binary clinical catalysts. The stock's beta of 1.376 and 140% YTD rally make it volatile for short-term trading. Long-term investors can benefit from potential commercialization and pipeline expansion, but must withstand significant drawdowns (max drawdown -24.95% in the past year). A minimum holding period of 2-3 years is recommended to allow clinical and regulatory milestones to materialize.